Tom McCarthy is the Executive Chairperson and Founder of Pathios Therapeutics, a clinical-stage oncology and immunology company, and Lucia Bio, focusing on innovative treatments for neuroinflammation. They also hold the position of Chairperson at Grey Wolf Therapeutics and serve as a Venture Partner at Brandon Capital. McCarthy co-founded Molecule to Medicine, overseeing the creation and scaling of biotech companies, and has significant experience in drug development, having previously been President, CEO, and Managing Director at Spinifex Pharmaceuticals, which was acquired by Novartis for approximately $700 million. Their career includes various leadership roles, including Non Executive Director positions at Kea Therapeutics and Trigemina, and extensive involvement in advancing drug candidates through clinical trials.
This person is not in the org chart